SPRY — ARS Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.35bn
- $1.04bn
- $89.15m
Annual cashflow statement for ARS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.9 | -89.5 | -34.7 | -54.4 | 8 |
| Depreciation | |||||
| Non-Cash Items | 3.74 | 20.3 | 7.04 | 2.36 | 7.28 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.63 | 1.6 | -12.8 | -7.33 | -1.81 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -31.2 | -66.8 | -40.1 | -59.3 | 13.5 |
| Capital Expenditures | -0.917 | -1.37 | -0.199 | -0.175 | -0.563 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -65.1 | — | -87 | -106 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.917 | -66.5 | -0.199 | -87.2 | -106 |
| Financing Cash Flow Items | -2.61 | 0 | 199 | 0 | 69.4 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 409 | 0.614 | 191 | 6.9 | 72.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 376 | -133 | 150 | -140 | -20.2 |